Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion

Similar documents
Final Kissing Ballooning Returns? The analysis of COBIS II registry

Side Branch Occlusion

PROMUS Element Experience In AMC

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

Why I try to avoid side branch dilatation

Debate Should we use FFR? I will say NO.

Hyeon-Cheol Gwon, On the behalf of SMART-DATE trial investigators ACC LBCT 2018

Unprotected LM intervention

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

LM stenting - Cypher

Abstract Background: Methods: Results: Conclusions:

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial

Bifurcation stenting with BVS

FFR-guided Jailed Side Branch Intervention

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.

Non-LM bifurcation studies of importance in 2011

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

In-Ho Chae. Seoul National University College of Medicine

New Double Stent Technique

The MAIN-COMPARE Study

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Post-Procedural Myocardial Injury or Infarction

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations

PCI for Long Coronary Lesion

Bifurcations Bad Krozingen I

Lessons learned From The National PCI Registry

Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy

DESolve NX Trial Clinical and Imaging Results

Supplementary Table S1: Proportion of missing values presents in the original dataset

1. Diabetes mellitus (DM) is associated with worse clinical and angiographic outcomes even in acute myocardial Infarction (AMI) patients.

Supplementary Material to Mayer et al. A comparative cohort study on personalised

Contemporary therapy of bifurcation lesions

Cover Page. The handle holds various files of this Leiden University dissertation

FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators

DECISION-CTO. Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion. Seung-Jung Park, MD., PhD.

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

Update from the Tryton IDE study

A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations

PCI vs. CABG From BARI to Syntax, Is The Game Over?

Percutaneous Intervention of Unprotected Left Main Disease

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

Bernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands

Clopidogrel Date: 15 July 2008

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

New Generation Drug- Eluting Stent in Korea

Diabetic Patients: Current Evidence of Revascularization

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

Complex PCI of an LAD/Diagonal bifurcation lesion (Medina 1,1,1) utilizing the DK Crush technique ".

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?

Approach to Multi Vessel disease with STEMI

STEMI AND MULTIVESSEL CORONARY DISEASE

COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

FFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT

A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.

FFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results. Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria

Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions

Cindy L. Grines MD FACC FSCAI

C. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller

PCI for Left Anterior Descending Artery Ostial Stenosis

Clinical Considerations for CTO

Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Journal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.

PCI Update Qesaria 2009

A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

ΣΥΜΠΛΟΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΔΙΧΑΣΜΩΝ

Coronary interventions

Benefit of Performing PCI Based on FFR

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Korea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea

Fractional Flow Reserve: Review of the latest data

When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER

APPENDIX F: CASE REPORT FORM

Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI

FRACTIONAL FLOW RESERVE: STANDARD OF CARE

Correlates of Adverse Events During Saphenous Vein Graft Intervention With Distal Embolic Protection

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Left Main Intervention: Will it become standard of care?

Journal of the American College of Cardiology Vol. 47, No. 8, by the American College of Cardiology Foundation ISSN /06/$32.

The MAIN-COMPARE Registry

Statistical analysis plan

Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2

eucalimus - First Experience

Acute Myocardial Infarction. Willis E. Godin D.O., FACC

PCI for In-Stent Restenosis. CardioVascular Research Foundation

DECISION - CTO. optimal Medical Treatment in patients with. Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators

Coronary microvascular dysfunction after elective percutaneous coronary intervention: correlation with exercise stress test results

Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

Transcription:

Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine

Dr. Hyeon-Cheol Gwon Research fund from Abbott Korea Boston Scientific Korea Medtronic Korea

Peri-procedural MI (PMI) Incidence About 5~30% Mechanisms Epicardial side-branch occlusion Compromise of the microvascular circulation No reflow Distal embolization

Definition of Peri-procedural MI in ARC Recommendation * By arbitrary convention, CK-MB or Troponin > 3 times URL * No solid scientific basis for defining a biomarker threshold * URL = upper reference level Cutlip DE, Circulation 2007

Many Studies Have Been Published Since 1994

Increased Mortality Dose-Dependently Meta-analysis for CK-MB (N=23,230) The risk of mortality from meta-analysis for CK-MB CK-MB > 1~3 URL HR=1.5 (1.2-1.8) CK-MB > 3-5 URL HR=1.8 (1.4-2.4) CK-MB > 5 URL HR=3.1 (2.3-4.2) * URL = upper reference level Ioannidis JPA, JACC 2003

Prognostic Value of PMI Meta-analysis for Troponin (N=15,581) Death for increased troponin Death or MI for increased troponin Nienhuis MB, CCI 2008 * PMI = peri-procedural MI

PMI as a Clinical Endpoint ARMYDA-ACS High dose statin before PCI BBC-One 1-stent vs. 2-stent in bifurcation lesion 1) Hildick-Smith D, BBC-ONE, Circulation 2010 2) Patti G, ARMYDA-ACS, JACC 2007 * PMI = peri-procedural MI

Argument Peri-procedural MI is not as prognostic as spontaneous MI * N=7,773 patients with NSTE-ACS from ACUITY Study Prasad A, JACC 2009 Hazard ratio for subsequent mortality Spontaneous MI: 7.5 (5.0-11.3, p=0.0001) Periprocedural MI: 1.3 (0.9-2.0, p=0.22) No information of level of enzyme elevation or infarct size

Case 1: Periprocedural MI M/68, exertional chest pain for 3 months Baseline CAG Stenting 3.0X18 mm Kissing ballooning Final CAG

Case 2: Spontaneous MI F/51, resting chest pain Baseline CAG Stenting 3.0X18 mm Final CAG

Same Infarct Size, Different Prognosis? Case 1: Periprocedural MI Case 2: Spontaneous MI MI volume: 14.4ml MI volume percentage: 13% MI volume: 12.8 ml MI volume percentage: 13%

Argument The adverse effect of PMI is not the result of myocardial injury, but the reflection of risk factors. Risk fa ctors PMI Clinica l event Not an independent predictor * PMI = peri-procedural MI

PMI in Risk Factor Subgroups The confounding effect of baseline risk factors cannot be fully controlled by any means. If we can analyze the data in each risk factor subgroup, we can reduce the confounding influence of risk factors on clinical event. Risk factors of PMI Hermann J. Peri-procedural myocardial injury: 2005 update, Eur Heart J 2005

Objective The aim of this study was to evaluate the prognosis of peri-procedural myocardial infarction (PMI) in rather homogenous clinical and lesion subset No myocardial infarction Coronary bifurcation lesion treated with drugeluting stent

Methods v From the COBIS (COronary BIfurcation Stenting) registry Inclusion criteria Ø Ø Coronary bifurcation lesions treated solely with at least 1 drug eluting stent Main vessel diameter 2.5 mm and side branch diameter 2.0 mm Exclusion criteria Ø Ø Ø Ø Ø Cardiogenic shock ST-segment elevation acute MI within 48 hours Left main coronary artery bifurcation lesion Myocardial infarction with or without ST elevation (N=229) CK-MB level not available (N=181) * Definition of PMI: peak CK-MB value > 3 times URL

Clinical Characteristics PMI (+) in 10.0% in 1188 patients PMI (+) (n = 119) PMI (-) (n = 1069) p-value Age (years) 65 ± 11 62 ± 10 0.005 Female 48 (40.3) 370 (34.6) 0.22 Diabetes mellitus 26 (21.8) 322 (30.1) 0.06 Smoking 33 (27.7) 240 (22.5) 0.19 Dyslipidemia 42 (35.3) 318 (29.7) 0.21 S-creatinine > 2.0 mg/dl 6 (5.0) 35 (3.3) 0.32 Unstable angina at presentation 70 (58.8) 514 (48.1) 0.033 Left ventricular ejection fraction (%) * 58 ± 11 61 ± 11 0.015 * PMI = peri-procedural myocardial infarction

Angiographic Characteristics PMI (+) PMI (-) p-value (n = 119) (n = 1069) LAD location 82 (68.9) 843 (78.9) 0.013 Multi-vessel disease 73 (61.9) 480 (44.9) < 0.001 Thrombus in main vessel 6 (5.0) 30 (2.8) 0.18 Bifurcation (by Medina classification) 0.89 0,0,1 0,1,0 0,1,1 1,0,0 1,0,1 1,1,0 1,1,1 3 (2.5) 13 (10.9) 15 (12.6) 3 (2.5) 8 (6.7) 13 (10.9) 64 (53.8) 15 (1.4) 108 (10.1) 141 (13.2) 66 (6.2) 64 (6.0) 117 (11.0) 557 (52.2) True bifurcation 87 (73.1) 762 (71.3) 0.69 * PMI = peri-procedural myocardial infarction

Procedural characteristics PMI (+) PMI (-) (n=119) (n=1069) p-value GP IIb/IIIa 5 (4.2) 31 (2.9) 0.43 Paclitaxel-eluting stent in main vessel 39 (33.1) 324 (30.8) 0.62 2-stent technique 26 (21.8) 207 (19.4) 0.52 Multi-lesion PCI 42 (39.6) 255 (27.0) 0.006 Stent total length in main vessel > 30 mm 62 (52.1) 457 (43.4) 0.07 Post-TIMI in main vessel < 3 3 (2.5) 3 (0.3) 0.016 Post-TIMI in side branch < 3 18 (15.1) 48 (4.5) < 0.001 Acute closure in main vessel 2 (1.7) 5 (0.5) 0.15 Acute closure in side branch 18 (15.1) 42 (3.9) < 0.001 Procedural success in main vessel 119 (97.5) 1058 (99.0) 0.16 Procedural success in side branch 69 (58.0) 745 (69.7) 0.009

Independent Risk Factors of PMI Adjusted HR 95% CI p Value Age 65 years 1.49 0.91-2.45 0.11 Unstable angina at presentation 1.37 0.83-2.25 0.22 LV EF < 50% 2.08 1.13-3.82 0.018 Multi-vessel disease 2.28 1.36-3.81 0.002 Location in LAD/diagonal 0.85 0.48-1.49 0.57 PCI-related acute closure in SB 3.34 1.23-9.02 0.018 Post-PCI TIMI <3 in main vessel 3.35 0.17-66.54 0.43 Post-PCI TIMI <3 in side branch 2.00 0.67-5.98 0.22 Final MLD in side branch 1.00 0.64-1.57 0.99 HR : hazard ratio, CI : confidence interval, LAD : left anterior descending coronary artery, TIMI : thro mbolysis in myocardial infarction, MLD : minimal luminal diameter

Clinical Outcomes (Median FU 22.7 months) PMI (+) (n = 119) PMI (-) (n = 1069) p Value Cardiac death 2.5 % 0.7 % 0.07 MI 0.8 % 1.1 % > 0.99 Cardiac death, or MI 3.4% 1.8% 0.28 Target lesion revascularization 3.4 % 5.0 % 0.65 Cerebrovascular accident 0.0 % 1.1 % 0.62 MACE 6.7% 6.3% 0.85 PMI : peri-procedural MI, PCI : percutaneous coronary intervention, TLR : target lesion revasc ularization, MACE: major adverse cardiac event = cardiac death, MI, or TLR

Cardiac Death Log-rank p=0.026 PMI no PMI

MACE Log-rank p=0.67 PMI no PMI MACE = cardiac death, MI, or TLR

Independent predictors of cardiac death HR 95% CI p Value Age 65 4.97 0.99-24.96 0.05 Cerebrovascular accident 2.04 0.41-10.08 0.38 Prior MI 2.31 0.46-11.67 0.31 Creatinine > 2.0 mg/dl 13.06 3.16-54.00 < 0.001 Unstable angina at presentation 2.22 0.56-8.76 0.25 Multi-vessel disease 1.28 0.30-5.59 0.74 Thrombus in main vessel 4.09 0.49-34.40 0.20 Peri-procedural MI 2.59 0.62-10.85 0.19 HR : hazard ratio, CI : confidence interval

Independent predictors of MACE HR 95% CI p-value Dyslipidemia 1.51 0.94-2.41 0.09 Creatinine > 2.0 mg/dl 3.67 1.65-8.18 0.001 Unstable angina at presentation 1.26 0.80-2.00 0.32 PES in main vessel 1.84 1.15-2.95 0.01 Stent length, total 30 mm in main vessel 2.15 1.34-3.46 0.002 Final kissing balloon inflation 2.33 1.45-3.75 0.001 Peri-procedural MI 1.07 0.51-2.23 0.86 HR : hazard ratio, CI : confidence interval, PES : paclitaxel- eluting stent

Limitations Retrospective study Post-PCI CK-MB was not systematically measured Lacked statistical power to detect a small difference of cardiac mortality

Conclusion Peri-procedural MI may not be a significant independent prognostic factor of cardiac death and MACE after coronary bifurcation stenting using contemporary intervention strategies. The larger studies are required to confirm this findings.